Pazopanib

What is Pazopanib?

Pazopanib is a prescription medication primarily used in oncology, belonging to a class of drugs known as multi-targeted receptor tyrosine kinase inhibitors (TKIs). It is also known by its brand name, Votrient. This potent oral agent is designed to interfere with the growth and spread of cancer cells by targeting specific proteins involved in tumor development and angiogenesis (the formation of new blood vessels that feed tumors). Its mechanism of action makes it a valuable tool in fighting certain types of advanced cancers, offering a targeted approach to therapy.

How Does it Work?

The efficacy of Pazopanib stems from its ability to selectively inhibit multiple receptor tyrosine kinases. Specifically, it targets vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), platelet-derived growth factor receptors (PDGFR-α and PDGFR-β), and c-KIT. By blocking these key signaling pathways, Pazopanib disrupts several critical processes essential for tumor survival and progression. It inhibits angiogenesis, effectively starving the tumor of its blood supply, and also directly impedes the proliferation and survival of cancer cells. This dual action makes Pazopanib a powerful antineoplastic agent, disrupting the complex biological mechanisms that drive tumor growth and metastasis.

Medical Uses

Pazopanib is approved for the treatment of two main types of cancer:

• Advanced Renal Cell Carcinoma (RCC)

  It is indicated for patients with advanced renal cell carcinoma, a type of kidney cancer. Pazopanib helps to slow the progression of the disease and improve outcomes in patients who have not previously received systemic therapy or who have received prior cytokine therapy.

• Advanced Soft Tissue Sarcoma (STS)

  Pazopanib is also used for the treatment of patients with advanced soft tissue sarcoma who have received prior chemotherapy. This includes various subtypes of STS, excluding gastrointestinal stromal tumor (GIST) and adipocytic sarcoma, demonstrating its broad utility within this complex group of cancers.

The decision to use Pazopanib is typically made by an oncologist, considering the patient's specific cancer type, stage, prior treatments, and overall health status.

Dosage

The standard recommended starting dose of Pazopanib is 800 mg taken orally once daily. It is crucial to administer Pazopanib without food, meaning at least one hour before or two hours after a meal. This timing is important to ensure optimal absorption and efficacy of the medication. Dosage adjustments may be necessary based on the patient's individual tolerability and the occurrence of adverse reactions. Physicians may reduce the dose in increments (e.g., to 400 mg, 200 mg) or temporarily interrupt treatment to manage side effects. It is vital for patients to adhere strictly to their prescribed dosage regimen and to never alter the dose without consulting their healthcare provider.

Side Effects

Like all potent cancer medications, Pazopanib can cause a range of side effects, some of which can be serious. Common side effects often include:

• Diarrhea
• Nausea and vomiting
• Fatigue and weakness
• Hypertension (high blood pressure)
• Hair color changes (depigmentation)
• Elevated liver enzymes (requiring regular monitoring)
• Headache
• Loss of appetite

More serious, though less common, side effects can include:

• Liver toxicity (hepatotoxicity)
• Cardiac dysfunction (e.g., QT prolongation, heart failure)
• Arterial thrombotic events (e.g., heart attack, stroke)
• Hemorrhage (bleeding)
• Gastrointestinal perforation or fistula
• Proteinuria (protein in the urine)
• Thyroid dysfunction

Patients should report any new or worsening symptoms to their doctor immediately. Regular monitoring, including blood tests for liver function and blood pressure checks, is essential during Pazopanib treatment.

Drug Interactions

Pazopanib is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme system. Therefore, it can interact with other drugs that inhibit or induce this enzyme, potentially altering Pazopanib's concentration in the body.

• CYP3A4 Inhibitors

  Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice) can increase Pazopanib levels, leading to increased toxicity. Dose reduction of Pazopanib may be necessary.

• CYP3A4 Inducers

  Conversely, strong CYP3A4 inducers (e.g., rifampin, phenytoin, St. John's Wort) can decrease Pazopanib levels, potentially reducing its efficacy.

• Drugs that Prolong QT Interval

  Pazopanib itself can prolong the QT interval; therefore, caution is advised when co-administering with other medications known to have this effect, as it may increase the risk of cardiac arrhythmias.

• Gastric pH Altering Agents

  Drugs that increase gastric pH (e.g., proton pump inhibitors, H2-receptor antagonists, antacids) can decrease Pazopanib solubility and absorption, potentially reducing its bioavailability. It is generally recommended to separate the administration of Pazopanib from these agents.

Patients must inform their healthcare provider about all medications, supplements, and herbal products they are taking to identify potential drug interactions.

FAQ

• What is Votrient?

  Votrient is the brand name for the generic drug Pazopanib, used for the treatment of advanced renal cell carcinoma and soft tissue sarcoma.

• How long do I need to take Pazopanib?

  The duration of Pazopanib treatment varies for each patient and depends on the response to therapy and the tolerability of side effects. Treatment typically continues as long as the benefits outweigh the risks and the disease remains controlled.

• Can Pazopanib cure cancer?

  Pazopanib is generally used to control the growth and spread of advanced cancers, prolonging life and improving quality of life, rather than providing a definitive cure. The goal is to manage the disease effectively.

• What foods or drinks should I avoid while taking Pazopanib?

  You should avoid grapefruit and grapefruit juice while taking Pazopanib, as they can interfere with the drug's metabolism and potentially increase side effects. Always follow your doctor's dietary advice.

Products containing Pazopanib are available through trusted online pharmacies. You can browse Pazopanib-based medications at ShipperVIP or Medicenter.

Summary

Pazopanib, marketed as Votrient, is a crucial multi-targeted tyrosine kinase inhibitor utilized in the treatment of advanced renal cell carcinoma and soft tissue sarcoma. Its mechanism involves disrupting key pathways that promote tumor growth and blood vessel formation. While offering significant therapeutic benefits, Pazopanib treatment requires careful management due to its potential for various side effects and drug interactions. Patients undergoing therapy with Pazopanib must adhere to prescribed dosages, report any adverse reactions promptly, and maintain open communication with their healthcare team to ensure optimal outcomes and safety.